Marizomib
Marizomib
Marizomib (pronunciation: /məˈrɪzoʊmɪb/) is a proteasome inhibitor used in the treatment of multiple myeloma. It is a beta-lactone-gamma-lactam compound that irreversibly binds to the proteasome and inhibits its function.
Etymology
The name "Marizomib" is derived from the genus Marizomus, a type of marine bacteria from which the drug was originally isolated. The suffix "-ib" is commonly used in the names of small molecule inhibitors.
Pharmacology
Marizomib inhibits the chymotrypsin-like activity of the 20S proteasome, a large protein complex that degrades unneeded or damaged proteins in the cell. By blocking the proteasome, marizomib disrupts the balance of proteins in the cell, leading to cell death.
Clinical Use
Marizomib is currently being investigated in clinical trials for the treatment of multiple myeloma and other malignant diseases. It has shown promise in preclinical studies for its ability to cross the blood-brain barrier, suggesting potential use in the treatment of brain tumors.
Related Terms
- Proteasome inhibitor
- Multiple myeloma
- Beta-lactone
- Gamma-lactam
- Proteasome
- Chymotrypsin
- Malignant
- Blood-brain barrier
- Brain tumors
External links
- Medical encyclopedia article on Marizomib
- Wikipedia's article - Marizomib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski